NextCure (Nasdaq:NXTC) - 주가, 뉴스 및 분석

NXTC 주식 개요

넥스트큐어는 임상 단계의 바이오 제약 회사로, 정상적인 면역 기능을 회복시켜 암 및 기타 면역 관련 질병을 치료하는 새로운 면역 의약품을 발굴하고 개발하는 데 주력하고 있습니다. 자세한 내용

NXTC 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

분석가들은 주가가 184.9% 상승할 것이라는 데 동의합니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

의미 있는 시가총액이 없습니다. ( $33M )

NextCure, Inc. 경쟁사

Tonix Pharmaceuticals Holding

NasdaqCM:TNXP

US$35.5m

Elevation Oncology

NasdaqGS:ELEV

US$37.6m

RAPT Therapeutics

NasdaqGM:RAPT

US$44.0m

CEL-SCI

NYSEAM:CVM

US$40.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 NextCure
과거 주가
현재 주가	US$1.17
52주 최고치	US$2.57
52주 최저치	US$1.03
베타	0.79
11개월 변경	-13.33%
3개월 변경 사항	-20.41%
1년 변경 사항	-2.50%
33년 변화	-79.55%
5년 변화	-97.67%
IPO 이후 변화	-94.12%

최근 뉴스 및 업데이트

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

Nov 13

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Jul 17

Recent updates

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08

NextCure provides update on NC318 clinical program

Dec 17

주주 수익률

	NXTC	US Biotechs	US 마켓
7D	-1.7%	2.5%	1.0%
1Y	-2.5%	15.6%	31.4%

수익률 대 산업: NXTC 지난 1년 동안 15.6 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: NXTC 지난 1년 동안 31.4 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is NXTC's price volatile compared to industry and market?
NXTC volatility
NXTC Average Weekly Movement	8.2%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

안정적인 주가: NXTC 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: NXTC 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2015	82	Michael Richman	www.nextcure.com

넥스트큐어는 임상 단계의 바이오 제약 회사로, 정상적인 면역 기능을 회복시켜 암 및 기타 면역 관련 질병을 치료하는 새로운 면역 의약품을 발굴 및 개발하는 데 주력하고 있습니다. 회사는 LAIR-1에 의해 매개되는 면역 억제를 차단하도록 설계된 면역 치료제인 NC410, 여러 종양 유형에서 발현되는 단백질인 B7-H4에 특이적으로 결합하는 단일 클론 항체 NC762, 조혈 줄기 세포를 포함한 정상 혈액 세포를 보존하면서 AML 모세포와 백혈병 줄기 세포를 기능적으로 죽이는 LAIR-1에 결합하는 단일 클론 항체 NC525를 개발 중입니다. 이 회사의 발견 및 연구 프로그램에는 다른 잠재적인 새로운 면역 조절 분자에 대한 전임상 평가 중인 항체도 포함됩니다.

NextCure, Inc. 기본 사항 요약

NextCure 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NXTC 기본 통계
시가총액	US$32.77m
수익(TTM)	-US$58.52m
수익(TTM)	n/a

0.0x

P/S 비율

-0.6x

P/E 비율

NXTC 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NXTC 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$58.52m
수익	-US$58.52m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.09
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

NXTC 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NXTC 주식 개요

보상

위험 분석

NextCure, Inc. 경쟁사

NasdaqCM:TNXP

US$35.5m

NasdaqGS:ELEV

US$37.6m

NasdaqGM:RAPT

US$44.0m

NYSEAM:CVM

US$40.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

Insufficient new directors

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Recent updates

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

Insufficient new directors

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Price target decreased by 25% to US$4.33

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

Price target decreased by 25% to US$4.33

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Price target increased to US$6.67

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Price target decreased to US$5.80

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Price target decreased to US$6.25

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Price target increased to US$14.14

NextCure GAAP EPS of -$0.59

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

High number of new directors

Now 23% undervalued after recent price drop

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

Price target decreased to US$16.75

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure: Large Upside With Downside Protected By Cash Pile

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

NextCure EPS misses by $0.01

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue behind estimates

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

New 90-day high: US$13.64

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer